|
1
|
Sharda AV, Barr AM, Harrison JA, Wilkie
AR, Fang C, Mendez LM, Ghiran IC, Italiano JE and Flaumenhaft R:
VWF maturation and release are controlled by 2 regulators of
Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood.
136:2824–2837. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Z and Li W: Formation and function
of Weibel-Palade bodies. Yi Chuan. 31:882–888. 2009.(In Chinese).
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holthenrich A and Gerke V: Regulation of
von-willebrand factor secretion from endothelial cells by the
annexin A2-S100A10 complex. Int J Mol Sci. 19:17522018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sadler JE: von Willebrand factor assembly
and secretion. J Thromb Haemost. 7 (Suppl 1):S24–S27. 2009.
View Article : Google Scholar
|
|
5
|
Kanaji S, Fahs SA, Shi Q, Haberichter SL
and Montgomery RR: Contribution of platelet vs endothelial VWF to
platelet adhesion and hemostasis. J Thromb Haemost. 10:1646–1652.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mourik M and Eikenboom J: Lifecycle of
Weibel-Palade bodies. Hamostaseologie. 37:13–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naß J, Terglane J and Gerke V: Weibel
Palade bodies: Unique secretory organelles of endothelial cells
that control blood vessel homeostasis. Front Cell Dev Biol.
9:8139952021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prasannan N and Scully M: Novel
antiplatelet strategies targeting VWF and GPIb. Platelets.
32:42–46. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pierre-Louis O, Resiere D, Alphonsine C,
Dantin F, Banydeen R, Dubois MD, Mehdaoui H and Neviere R:
Increased binding of von willebrand factor to sub-endothelial
collagen may facilitate thrombotic events complicating bothrops
lanceolatus envenomation in humans. Toxins (Basel). 15:4412023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thompson AR: Structure and function of the
factor VIII gene and protein. Semin Thromb Hemost. 29:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lenting PJ, Casari C, Christophe OD and
Denis CV: von Willebrand factor: The old, the new and the unknown.
J Thromb Haemost. 10:2428–2437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwameis M, Schörgenhofer C, Assinger A,
Steiner MM and Jilma B: VWF excess and ADAMTS13 deficiency: A
unifying pathomechanism linking inflammation to thrombosis in DIC,
malaria, and TTP. Thromb Haemost. 113:708–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishihara J, Ishihara A, Starke RD,
Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV,
Fukunaga K, et al: The heparin binding domain of von Willebrand
factor binds to growth factors and promotes angiogenesis in wound
healing. Blood. 133:2559–2569. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mochizuki S, Soejima K, Shimoda M, Abe H,
Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on
carcinoma cell metastasis by cleavage of von Willebrand factor. J
Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Desch A, Strozyk EA, Bauer AT, Huck V,
Niemeyer V, Wieland T and Schneider SW: Highly invasive melanoma
cells activate the vascular endothelium via an MMP-2/integrin
αvβ5-induced secretion of VEGF-A. Am J Pathol. 181:693–705. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goerge T, Barg A, Schnaeker EM, Poppelmann
B, Shpacovitch V, Rattenholl A, Maaser C, Luger TA, Steinhoff M and
Schneider SW: Tumor-derived matrix metalloproteinase-1 targets
endothelial proteinase-activated receptor 1 promoting endothelial
cell activation. Cancer Res. 66:7766–7774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goertz L, Schneider SW, Desch A, Mayer FT,
Koett J, Nowak K, Karampinis I, Bohlmann MK, Umansky V and Bauer
AT: Heparins that block VEGF-A-mediated von Willebrand factor fiber
generation are potent inhibitors of hematogenous but not lymphatic
metastasis. Oncotarget. 7:68527–68545. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
John A, Robador JR, Vidal-Y-Sy S, Houdek
P, Wladykowski E, Günes C, Bolenz C, Schneider SW, Bauer AT and
Gorzelanny C: Urothelial carcinoma of the bladder induces
endothelial cell activation and hypercoagulation. Mol Cancer Res.
18:1099–1109. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang P, Goodrich C, Fu C and Dong C:
Melanoma upregulates ICAM-1 expression on endothelial cells through
engagement of tumor CD44 with endothelial E-selectin and activation
of a PKCα-p38-SP-1 pathway. FASEB J. 28:4591–4609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bauer AT, Suckau J, Frank K, Desch A,
Goertz L, Wagner AH, Hecker M, Goerge T, Umansky L, Beckhove P, et
al: von Willebrand factor fibers promote cancer-associated platelet
aggregation in malignant melanoma of mice and humans. Blood.
125:3153–3163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goerge T, Kleinerüschkamp F, Barg A,
Schnaeker EM, Huck V, Schneider MF, Steinhoff M and Schneider SW:
Microfluidic reveals generation of platelet-strings on
tumor-activated endothelium. Thromb Haemost. 98:283–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCarty OJ, Mousa SA, Bray PF and
Konstantopoulos K: Immobilized platelets support human colon
carcinoma cell tethering, rolling, and firm adhesion under dynamic
flow conditions. Blood. 96:1789–1797. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morganti M, Carpi A, Amo-Takyi B,
Sagripanti A, Nicolini A, Giardino R and Mittermayer C: Von
Willebrand's factor mediates the adherence of human tumoral cells
to human endothelial cells and ticlopidine interferes with this
effect. Biomed Pharmacother. 54:431–436. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feinauer MJ, Schneider SW, Berghoff AS,
Robador JR, Tehranian C, Karreman MA, Venkataramani V, Solecki G,
Grosch JK, Gunkel K, et al: Local blood coagulation drives cancer
cell arrest and brain metastasis in a mouse model. Blood.
137:1219–1232. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blann AD, Gurney D, Wadley M, Bareford D,
Stonelake P and Lip GY: Increased soluble P-selectin in patients
with haematological and breast cancer: A comparison with
fibrinogen, plasminogen activator inhibitor and von Willebrand
factor. Blood Coagul Fibrinolysis. 12:43–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blann AD, Balakrishnan B, Shantsila E,
Ryan P and Lip GY: Endothelial progenitor cells and circulating
endothelial cells in early prostate cancer: A comparison with
plasma vascular markers. Prostate. 71:1047–1053. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH,
Yen CC and Chen PM: Plasma von Willebrand factor level as a
prognostic indicator of patients with metastatic colorectal
carcinoma. World J Gastroenterol. 11:2166–2170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gil-Bazo I, Catalán Goni V, Alonso
Gutiérrez A, Rodríguez Rodríguez J, Páramo Fernández JA, de la
Cámara Gómez J, Hernández Lizoain JL and García-Foncillas López J:
Impact of surgery and chemotherapy on von Willebrand factor and
vascular endothelial growth factor levels in colorectal cancer.
Clin Transl Oncol. 7:150–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang AJ, Wang M, Wang Y, Cai W, Li Q, Zhao
TT, Zhang LH, Houck K, Chen X, Jin YL, et al: Cancer cell-derived
von Willebrand factor enhanced metastasis of gastric
adenocarcinoma. Oncogenesis. 7:122018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Colonne CK, Favaloro EJ and Pasalic L: The
intriguing connections between von Willebrand factor, ADAMTS13 and
cancer. Healthcare (Basel). 10:5572022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meschengieser S, Blanco A, Woods A,
Maugeri N, Fernandez J, Dupont J and Lazzari MA: Intraplatelet
levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
Thromb Res. 48:311–319. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Franchini M, Di Perna C, Santoro C,
Castaman G, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S,
Coppola A, et al: Cancers in patients with von Willebrand disease:
A survey from the italian association of haemophilia centres. Semin
Thromb Hemost. 42:36–41. 2016.PubMed/NCBI
|
|
35
|
Ablin RJ, Bartkus JM and Gonder MJ:
Immunoquantitation of factor VIII-related antigen (von Willebrand
factor antigen) in prostate cancer. Cancer Lett. 40:283–289. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Athale U, Moghrabi A, Nayiager T, Delva
YL, Thabane L and Chan AKC: von Willebrand factor and thrombin
activation in children with newly diagnosed acute lymphoblastic
leukemia: An impact of peripheral blasts. Pediatr Blood Cancer.
54:963–969. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Damin DC, Rosito MA, Gus P, Roisemberg I,
Bandinelli E and Schwartsmann G: Von Willebrand factor in
colorectal cancer. Int J Colorectal Dis. 17:42–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo R, Yang J, Liu X, Wu J and Chen Y:
Increased von Willebrand factor over decreased ADAMTS-13 activity
is associated with poor prognosis in patients with advanced
non-small-cell lung cancer. J Clin Lab Anal. 32:e222192018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mannucci PM, Karimi M, Mosalaei A,
Canciani MT and Peyvandi F: Patients with localized and
disseminated tumors have reduced but measurable levels of ADAMTS-13
(von Willebrand factor cleaving protease). Haematologica.
88:454–458. 2003.PubMed/NCBI
|
|
40
|
Pépin M, Kleinjan A, Hajage D, Büller HR,
Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A and
Mahé I: ADAMTS-13 and von Willebrand factor predict venous
thromboembolism in patients with cancer. J Thromb Haemost.
14:306–315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Röhsig LM, Damin DC, Stefani SD, Castro CG
Jr, Roisenberg I and Schwartsmann G: von Willebrand factor antigen
levels in plasma of patients with malignant breast disease. Braz J
Med Biol Res. 34:1125–1129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yigit E, Gönüllü G, Yücel I, Turgut M,
Erdem D and Cakar B: Relation between hemostatic parameters and
prognostic/predictive factors in breast cancer. Eur J Intern Med.
19:602–607. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zietek Z, Iwan-Zietek I, Paczulski R,
Kotschy M and Wolski Z: von Willebrand factor antigen in blood
plasma of patients with urinary bladder carcinoma. Thromb Res.
83:399–402. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dhami SPS, Patmore S, Comerford C, Byrne
CM, Cavanagh B, Castle J, Kirwan CC, Kenny M, Schoen I, O'Donnell
JS and O'Sullivan JM: Breast cancer cells mediate endothelial cell
activation, promoting von Willebrand factor release, tumor
adhesion, and transendothelial migration. J Thromb Haemost.
20:2350–2365. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lehrer S, Green S, Dembitzer FR,
Rheinstein PH and Rosenzweig KE: Increased RNA expression of von
willebrand factor gene is associated with infiltrating lobular
breast cancer and normal PAM50 subtype. Cancer Genomics Proteomics.
16:147–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Knöfler R, Lange BS, Paul F, Tiebel O and
Suttorp M: Bleeding signs due to acquired von Willebrand syndrome
at diagnosis of chronic myeloid leukaemia in children. Br J
Haematol. 188:701–706. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Conlan MG, Folsom AR, Finch A, Davis CE,
Sorlie P, Marcucci G and Wu KK: Associations of factor VIII and von
Willebrand factor with age, race, sex, and risk factors for
atherosclerosis. The atherosclerosis risk in communities (ARIC)
study. Thromb Haemost. 70:380–385. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bick RL: Alterations of hemostasis
associated with malignancy: Etiology, pathophysiology, diagnosis
and management. Semin Thromb Hemost. 5:1–26. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kwaan HC and Lindholm PF: Fibrin and
fibrinolysis in cancer. Semin Thromb Hemost. 45:413–422. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Senger DR: Molecular framework for
angiogenesis: A complex web of interactions between extravasated
plasma proteins and endothelial cell proteins induced by angiogenic
cytokines. Am J Pathol. 149:1–7. 1996.PubMed/NCBI
|
|
51
|
Lip GYH, Chin BSP and Blann AD: Cancer and
the prothrombotic state. Lancet Oncol. 3:27–34. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sørensen HT, Mellemkjaer L, Steffensen FH,
Olsen JH and Nielsen GL: The risk of a diagnosis of cancer after
primary deep venous thrombosis or pulmonary embolism. N Engl J Med.
338:1169–1173. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Y, Li L, Dong F, Guo L, Hou Y, Hu H,
Yan S, Zhou X, Liao L, Allen TD and Liu JU: Plasma von Willebrand
factor level is transiently elevated in a rat model of acute
myocardial infarction. Exp Ther Med. 10:1743–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu J, Kanki Y, Okada Y, Jin E, Yano K,
Shih SC, Minami T and Aird WC: A +220 GATA motif mediates basal but
not endotoxin-repressible expression of the von Willebrand factor
promoter in Hprt-targeted transgenic mice. J Thromb Haemost.
7:1384–1392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu Y, Pan S, Liu J, Dong F, Cheng Z, Zhang
J, Qi R, Zang Q, Zhang C, Wang X, et al: GATA3-induced vWF
upregulation in the lung adenocarcinoma vasculature. Oncotarget.
8:110517–110529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fan M, Wang X, Peng X, Feng S, Zhao J,
Liao L, Zhang Y, Hou Y and Liu J: Prognostic value of plasma von
Willebrand factor levels in major adverse cardiovascular events: a
systematic review and meta-analysis. BMC Cardiovasc Disord.
20:722020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Peng X, Wang X, Fan M, Zhao J, Lin L and
Liu J: Plasma levels of von Willebrand factor in type 2 diabetes
patients with and without cardiovascular diseases: A meta-analysis.
Diabetes Metab Res Rev. 36:e31932020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang X, Zhao J, Zhang Y, Xue X, Yin J,
Liao L, Xu C, Hou Y, Yan S and Liu J: Kinetics of plasma von
Willebrand factor in acute myocardial infarction patients: A
meta-analysis. Oncotarget. 8:90371–90379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Comerford C, Glavey S, Quinn J and
O'Sullivan JM: The role of VWF/FVIII in thrombosis and cancer
progression in multiple myeloma and other hematological
malignancies. J Thromb Haemost. 20:1766–1777. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Terraube V, Marx I and Denis CV: Role of
von Willebrand factor in tumor metastasis. Thromb Res. 120 (Suppl
2):S64–S70. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Suter CM, Hogg PJ, Price JT, Chong BH and
Ward RL: Identification and characterisation of a platelet
GPIb/V/IX-like complex on human breast cancers: Implications for
the metastatic process. Jpn J Cancer Res. 92:1082–1092. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang X, Starodubtseva MN, Kapron CM and
Liu J: Cadmium, von Willebrand factor and vascular aging. NPJ
Aging. 9:112023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang X, Dong F, Wang F, Yan S, Chen X,
Tozawa H, Ushijima T, Kapron CM, Wada Y and Liu J: Low dose cadmium
upregulates the expression of von Willebrand factor in endothelial
cells. Toxicol Lett. 290:46–54. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Signal Transduct Target Ther. 5:282020.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Nierodzik ML, Plotkin A, Kajumo F and
Karpatkin S: Thrombin stimulates tumor-platelet adhesion in vitro
and metastasis in vivo. J Clin Invest. 87:229–236. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Schulze EB, Hedley BD, Goodale D, Postenka
CO, Al-Katib W, Tuck AB, Chambers AF and Allan AL: The thrombin
inhibitor Argatroban reduces breast cancer malignancy and
metastasis via osteopontin-dependent and osteopontin-independent
mechanisms. Breast Cancer Res Treat. 112:243–254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nierodzik ML, Kajumo F and Karpatkin S:
Effect of thrombin treatment of tumor cells on adhesion of tumor
cells to platelets in vitro and tumor metastasis in vivo. Cancer
Res. 52:3267–3272. 1992.PubMed/NCBI
|
|
68
|
Floyd CM, Irani K, Kind PD and Kessler CM:
von Willebrand factor interacts with malignant hematopoietic cell
lines: Evidence for the presence of specific binding sites and
modification of von Willebrand factor structure and function. J Lab
Clin Med. 119:467–476. 1992.PubMed/NCBI
|
